CGEM logo

CGEMCullinan Oncology Inc

$12.65
$0.33
(2.54%)
Pre-Market
Updated: 05:39 AM EDT·Prev Close $12.98
EarningsAug 6
Mkt Cap$740.57M
Vol74.00
News
all
press releases
Why Marvell Technology Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
href=https://www.benzinga.com/quote/RMSG target=_blank>(NASDAQ: RMSG) lost 67.6% to $0.69 in pre-market trading. The company recently announced a 1-for-20 reverse stock split.The shares of Marvell Technology Inc (NASDAQ: MRVL) surged in pre-market trading after securing a spot in the S&P 500...
Benzinga
News Placeholder
More News
News Placeholder
Upcoming Phase 2 Readouts Could Redefine These Biotech Stocks
Upcoming Phase 2 Readouts Could Redefine These Biotech Stocks $NTHI, $ORKA, $ABVX, $CGEM, $SYRE, $APGE
24-7 Market News
News Placeholder
The Biology Came First.
MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at...
Business Wire
News Placeholder
Jennifer Michaelson Sells 8,000 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock
Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) insider Jennifer Michaelson sold 8,000 shares of the business's stock in a transaction that occurred on Tuesday, May 5th. The shares were...
MarketBeat
News Placeholder
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 5.6% - Time to Sell?
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 5.6% - Here's What Happened...
MarketBeat
News Placeholder
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Rating of "Moderate Buy" by Brokerages
Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the ten analysts that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a h...
MarketBeat
News Placeholder
Cullinan Therapeutics (NASDAQ:CGEM) Trading 8.5% Higher - Here's Why
Cullinan Therapeutics (NASDAQ:CGEM) Trading Up 8.5% - Time to Buy...
MarketBeat
News Placeholder
Cullinan Therapeutics (NASDAQ:CGEM) Receives "Buy" Rating from BTIG Research
BTIG Research reiterated a "buy" rating and issued a $38.00 price objective on shares of Cullinan Therapeutics in a report on Monday...
MarketBeat
News Placeholder
Research Analysts Issue Forecasts for CGEM Q1 Earnings
Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Analysts at HC Wainwright lifted their Q1 2026 earnings per share (EPS) estimates for Cullinan Therapeutics in a research report issued to...
MarketBeat
News Placeholder
Cullinan Therapeutics (CGEM) Expected to Announce Quarterly Earnings on Thursday
Cullinan Therapeutics (NASDAQ:CGEM) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.